Lundbeck enters the hunt for schizophrenia biomarkers

“The perspectives in the consortium are great. The ability to reliably measure a biomarker may play a critical predictive role in schizophrenia drug development. If the work turns out as we hope, it can speed up research and development of treatments in schizophrenia,” says Bruce Kinon, MD and US Therapeutic Area Head, Psychosis in Clinical Affairs & Operations, who is involved in the steering committee of the consortium on behalf of Lundbeck.

3 Likes

That’s great news man.

3 Likes

I think there are a lot of groups working on this. Lundbeck is a big one though. They currently have 2 compounds in clinical development (phase 1 and 2) for negative symptoms and for cognitive impairment.

Lu AF88434 (PDE1 inhibitor) and
Lu AF11167 (PDE10 inhibitor)

2 Likes